Imagion Biosystems (ASX:IBX) Total Payout Ratio : 1.51 (As of May. 07, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Imagion Biosystems Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Imagion Biosystems's current Total Payout Ratio is 1.51.

Imagion Biosystems Total Payout Ratio Historical Data

The historical data trend for Imagion Biosystems's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imagion Biosystems Total Payout Ratio Chart

Imagion Biosystems Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Payout Ratio

Get a 7-Day Free Trial

2.75

0.91

0.18

1.51

Imagion Biosystems Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Payout Ratio	Get a 7-Day Free Trial											-	0.34	-0.04	0.14	5.38

Competitive Comparison of Imagion Biosystems's Total Payout Ratio

For the Diagnostics & Research subindustry, Imagion Biosystems's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imagion Biosystems's Total Payout Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Imagion Biosystems's Total Payout Ratio falls into.

Save Embed

;

Save Embed

;

Imagion Biosystems Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Imagion Biosystems's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	3.125	+	0)	/	-2.067
	=	1.51

Imagion Biosystems's Total Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	2.905	+	0)	/	-0.54
	=	5.38

Imagion Biosystems Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Imagion Biosystems's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Imagion Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Imagion Biosystems Ltd (ASX:IBX) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

IBXXF:USA

Address

5601 Oberlin Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.imagionbiosystems.com

Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.

Imagion Biosystems Headlines

No Headlines